http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 02 Jun 2026 16:16:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++4++++++++++SUTRO+BIOPHARMA%2C+INC.+++++For%3A+Jun+02++Filed+by%3A+Chow+Gregory+K./26591916.html si-local-file:///var/storage/secattach/20260602/26591916.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++SUTRO+BIOPHARMA%2C+INC.+++++For%3A+Jun+02++Filed+by%3A+Chow+Gregory+K./26591916.html Tue, 02 Jun 2026 16:16:00 -0400 O.02325435 STRO http://www.streetinsider.com/SEC+Filings/Form++4++++++++++SUTRO+BIOPHARMA%2C+INC.+++++For%3A+Jun+02++Filed+by%3A+Chow+Gregory+K./26591916.html si-local-file:///var/storage/secattach/20260602/26591916.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++SUTRO+BIOPHARMA%2C+INC.+++++For%3A+Jun+02++Filed+by%3A+Chow+Gregory+K./26591916.html Tue, 02 Jun 2026 16:16:00 -0400 O.02325435 STRO http://www.streetinsider.com/Investing/Barclays+initiates+oncology-focused+biotechs+with+positive+outlook/26563509.html <p>Investing.com -- Barclays initiated coverage of four small- and mid-cap biotechnology companies in a note to clients on Thursday, calling the stocks differentiated platform plays with the potential to deliver meaningful advances across tumor types and treatment modalities.</p> <p></p> <p dir="ltr">Alpha Tau Medical, Cellectis, Immunome and Sutro Biopharma were all assigned Overweight ratings</p> <p dir="ltr">Analyst Lukas Shumway told investors that while biotech investments carry binary risk, "investments made on the backs of differentiated platforms with sound scientific rationale, prior clinical data, and de-risked mechanisms skew that risk-reward to the upside."</p> <p dir="ltr">Sutro and <span itemscope="" itemtype="http://schema.org/Corporation"><span itemprop="name">Immunome</span></span> both operate in the antibody-drug conjugate space, which http://www.streetinsider.com/Investing/Barclays+initiates+oncology-focused+biotechs+with+positive+outlook/26563509.html Thu, 28 May 2026 11:05:56 -0400 CLLS IMNM STRO http://www.streetinsider.com/Investing/Barclays+initiates+oncology-focused+biotechs+with+positive+outlook/26563509.html <p>Investing.com -- Barclays initiated coverage of four small- and mid-cap biotechnology companies in a note to clients on Thursday, calling the stocks differentiated platform plays with the potential to deliver meaningful advances across tumor types and treatment modalities.</p> <p></p> <p dir="ltr">Alpha Tau Medical, Cellectis, Immunome and Sutro Biopharma were all assigned Overweight ratings</p> <p dir="ltr">Analyst Lukas Shumway told investors that while biotech investments carry binary risk, "investments made on the backs of differentiated platforms with sound scientific rationale, prior clinical data, and de-risked mechanisms skew that risk-reward to the upside."</p> <p dir="ltr">Sutro and <span itemscope="" itemtype="http://schema.org/Corporation"><span itemprop="name">Immunome</span></span> both operate in the antibody-drug conjugate space, which http://www.streetinsider.com/Investing/Barclays+initiates+oncology-focused+biotechs+with+positive+outlook/26563509.html Thu, 28 May 2026 11:05:56 -0400 CLLS IMNM STRO http://www.streetinsider.com/Investing/Barclays+initiates+oncology-focused+biotechs+with+positive+outlook/26563509.html <p>Investing.com -- Barclays initiated coverage of four small- and mid-cap biotechnology companies in a note to clients on Thursday, calling the stocks differentiated platform plays with the potential to deliver meaningful advances across tumor types and treatment modalities.</p> <p></p> <p dir="ltr">Alpha Tau Medical, Cellectis, Immunome and Sutro Biopharma were all assigned Overweight ratings</p> <p dir="ltr">Analyst Lukas Shumway told investors that while biotech investments carry binary risk, "investments made on the backs of differentiated platforms with sound scientific rationale, prior clinical data, and de-risked mechanisms skew that risk-reward to the upside."</p> <p dir="ltr">Sutro and <span itemscope="" itemtype="http://schema.org/Corporation"><span itemprop="name">Immunome</span></span> both operate in the antibody-drug conjugate space, which http://www.streetinsider.com/Investing/Barclays+initiates+oncology-focused+biotechs+with+positive+outlook/26563509.html Thu, 28 May 2026 11:05:56 -0400 CLLS IMNM STRO http://www.streetinsider.com/General+News/Barclays+initiates+oncology-focused+biotechs+with+positive+outlook/26563509.html <p>Investing.com -- Barclays initiated coverage of four small- and mid-cap biotechnology companies in a note to clients on Thursday, calling the stocks differentiated platform plays with the potential to deliver meaningful advances across tumor types and treatment modalities.</p> <p></p> <p dir="ltr">Alpha Tau Medical, Cellectis, Immunome and Sutro Biopharma were all assigned Overweight ratings</p> <p dir="ltr">Analyst Lukas Shumway told investors that while biotech investments carry binary risk, "investments made on the backs of differentiated platforms with sound scientific rationale, prior clinical data, and de-risked mechanisms skew that risk-reward to the upside."</p> <p dir="ltr">Sutro and <span itemscope="" itemtype="http://schema.org/Corporation"><span itemprop="name">Immunome</span></span> both operate in the antibody-drug conjugate space, which http://www.streetinsider.com/General+News/Barclays+initiates+oncology-focused+biotechs+with+positive+outlook/26563509.html Thu, 28 May 2026 11:05:56 -0400 CLLS IMNM STRO http://www.streetinsider.com/General+News/Barclays+initiates+oncology-focused+biotechs+with+positive+outlook/26563509.html <p>Investing.com -- Barclays initiated coverage of four small- and mid-cap biotechnology companies in a note to clients on Thursday, calling the stocks differentiated platform plays with the potential to deliver meaningful advances across tumor types and treatment modalities.</p> <p></p> <p dir="ltr">Alpha Tau Medical, Cellectis, Immunome and Sutro Biopharma were all assigned Overweight ratings</p> <p dir="ltr">Analyst Lukas Shumway told investors that while biotech investments carry binary risk, "investments made on the backs of differentiated platforms with sound scientific rationale, prior clinical data, and de-risked mechanisms skew that risk-reward to the upside."</p> <p dir="ltr">Sutro and <span itemscope="" itemtype="http://schema.org/Corporation"><span itemprop="name">Immunome</span></span> both operate in the antibody-drug conjugate space, which http://www.streetinsider.com/General+News/Barclays+initiates+oncology-focused+biotechs+with+positive+outlook/26563509.html Thu, 28 May 2026 11:05:56 -0400 CLLS IMNM STRO http://www.streetinsider.com/General+News/Barclays+initiates+oncology-focused+biotechs+with+positive+outlook/26563509.html <p>Investing.com -- Barclays initiated coverage of four small- and mid-cap biotechnology companies in a note to clients on Thursday, calling the stocks differentiated platform plays with the potential to deliver meaningful advances across tumor types and treatment modalities.</p> <p></p> <p dir="ltr">Alpha Tau Medical, Cellectis, Immunome and Sutro Biopharma were all assigned Overweight ratings</p> <p dir="ltr">Analyst Lukas Shumway told investors that while biotech investments carry binary risk, "investments made on the backs of differentiated platforms with sound scientific rationale, prior clinical data, and de-risked mechanisms skew that risk-reward to the upside."</p> <p dir="ltr">Sutro and <span itemscope="" itemtype="http://schema.org/Corporation"><span itemprop="name">Immunome</span></span> both operate in the antibody-drug conjugate space, which http://www.streetinsider.com/General+News/Barclays+initiates+oncology-focused+biotechs+with+positive+outlook/26563509.html Thu, 28 May 2026 11:05:56 -0400 CLLS IMNM STRO http://www.streetinsider.com/New+Coverage/Barclays+Starts+Sutro+Biopharma+%28STRO%29+at+Overweight/26560064.html (Updated - May 28, 2026 3:43 AM EDT) <p>Barclays analyst Lukas Shumway initiates coverage on Sutro Biopharma (NASDAQ: STRO) with a Overweight rating and a price target of $56.00.</p><p>The analyst comments: “We initiate coverage of Sutro Bio (STRO) at Overweight with a $56 price target. Sutro Bio is a biopharmaceutical company focused on the development of antibody-drug conjugates (ADCs) for the treatment of various cancers. The company uses a cell-free antibody generation platform that allows for increased specificity and fidelity of ADC payload conjugation, potentially increasing efficacy and safety. The company's lead asset STRO-004 is a tissue factor-targeting ADC being evaluated http://www.streetinsider.com/New+Coverage/Barclays+Starts+Sutro+Biopharma+%28STRO%29+at+Overweight/26560064.html Thu, 28 May 2026 03:43:50 -0400 STRO http://www.streetinsider.com/Analyst+Comments/Barclays+Starts+Sutro+Biopharma+%28STRO%29+at+Overweight/26560064.html (Updated - May 28, 2026 3:43 AM EDT) <p>Barclays analyst Lukas Shumway initiates coverage on Sutro Biopharma (NASDAQ: STRO) with a Overweight rating and a price target of $56.00.</p><p>The analyst comments: “We initiate coverage of Sutro Bio (STRO) at Overweight with a $56 price target. Sutro Bio is a biopharmaceutical company focused on the development of antibody-drug conjugates (ADCs) for the treatment of various cancers. The company uses a cell-free antibody generation platform that allows for increased specificity and fidelity of ADC payload conjugation, potentially increasing efficacy and safety. The company's lead asset STRO-004 is a tissue factor-targeting ADC being evaluated http://www.streetinsider.com/Analyst+Comments/Barclays+Starts+Sutro+Biopharma+%28STRO%29+at+Overweight/26560064.html Thu, 28 May 2026 03:43:50 -0400 STRO http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++SUTRO+BIOPHARMA%2C+INC.++++++++++++++++++Filed+by%3A+Samsara+BioCapital%2C+L.P./26507075.html si-local-file:///var/storage/secattach/20260515/26507075.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++SUTRO+BIOPHARMA%2C+INC.++++++++++++++++++Filed+by%3A+Samsara+BioCapital%2C+L.P./26507075.html Fri, 15 May 2026 16:45:00 -0400 O.02325435 STRO http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++SUTRO+BIOPHARMA%2C+INC.++++++++++++++++++Filed+by%3A+Samsara+BioCapital%2C+L.P./26507075.html si-local-file:///var/storage/secattach/20260515/26507075.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++SUTRO+BIOPHARMA%2C+INC.++++++++++++++++++Filed+by%3A+Samsara+BioCapital%2C+L.P./26507075.html Fri, 15 May 2026 16:45:00 -0400 O.02325435 STRO http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++SUTRO+BIOPHARMA%2C+INC.++++++++++++++++++Filed+by%3A+Kynam+Capital+Management%2C+LP/26504670.html si-local-file:///var/storage/secattach/20260515/26504670.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++SUTRO+BIOPHARMA%2C+INC.++++++++++++++++++Filed+by%3A+Kynam+Capital+Management%2C+LP/26504670.html Fri, 15 May 2026 16:02:00 -0400 O.02325435 STRO http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++SUTRO+BIOPHARMA%2C+INC.++++++++++++++++++Filed+by%3A+Kynam+Capital+Management%2C+LP/26504670.html si-local-file:///var/storage/secattach/20260515/26504670.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++SUTRO+BIOPHARMA%2C+INC.++++++++++++++++++Filed+by%3A+Kynam+Capital+Management%2C+LP/26504670.html Fri, 15 May 2026 16:02:00 -0400 O.02325435 STRO http://www.streetinsider.com/Upgrades/Wedbush+Upgrades+Sutro+Biopharma+%28STRO%29+to+Outperform/26498794.html <p>Wedbush analyst David Nierengarten upgraded Sutro Biopharma (NASDAQ: STRO) from Neutral to Outperform with a price target of $60.00 (from $22.00).</p><p>For an analyst ratings summary and ratings history on Sutro Biopharma <a href="http://www.streetinsider.com/rating_history.php?q=STRO">click here</a>. For more ratings news on Sutro Biopharma <a href="http://www.streetinsider.com/stock_lookup_news.php?q=STRO&amp;type=analyst">click here</a>.</p><p>Shares of Sutro Biopharma closed at $38.42 yesterday.</p> http://www.streetinsider.com/Upgrades/Wedbush+Upgrades+Sutro+Biopharma+%28STRO%29+to+Outperform/26498794.html Fri, 15 May 2026 06:34:51 -0400 STRO http://www.streetinsider.com/Earnings/Sutro+Biopharma+Inc.+%28STRO%29+Misses+Q1+EPS+by+294c/26496264.html <p>Sutro Biopharma Inc. (NASDAQ: STRO) reported Q1 EPS of ($2.94). Revenue for the quarter came in at $14.52 million.</p><p>For earnings history and earnings-related data on Sutro Biopharma Inc. (STRO) <a href="http://www.streetinsider.com/ec_earnings.php?q=STRO">click here</a>.</p> http://www.streetinsider.com/Earnings/Sutro+Biopharma+Inc.+%28STRO%29+Misses+Q1+EPS+by+294c/26496264.html Thu, 14 May 2026 16:56:34 -0400 STRO http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++SUTRO+BIOPHARMA%2C+INC.+++++For%3A+Mar+31/26495740.html si-local-file:///var/storage/secattach/20260514/26495740.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++SUTRO+BIOPHARMA%2C+INC.+++++For%3A+Mar+31/26495740.html Thu, 14 May 2026 16:31:00 -0400 O.02325435 STRO http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++SUTRO+BIOPHARMA%2C+INC.+++++For%3A+Mar+31/26495740.html si-local-file:///var/storage/secattach/20260514/26495740.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++SUTRO+BIOPHARMA%2C+INC.+++++For%3A+Mar+31/26495740.html Thu, 14 May 2026 16:31:00 -0400 O.02325435 STRO http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++SUTRO+BIOPHARMA%2C+INC.+++++For%3A+May+14/26495184.html si-local-file:///var/storage/secattach/20260514/26495184.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++SUTRO+BIOPHARMA%2C+INC.+++++For%3A+May+14/26495184.html Thu, 14 May 2026 16:16:00 -0400 O.02325435 STRO http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++SUTRO+BIOPHARMA%2C+INC.+++++For%3A+May+14/26495184.html si-local-file:///var/storage/secattach/20260514/26495184.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++SUTRO+BIOPHARMA%2C+INC.+++++For%3A+May+14/26495184.html Thu, 14 May 2026 16:16:00 -0400 O.02325435 STRO http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++SUTRO+BIOPHARMA%2C+INC.++++++++++++++++++Filed+by%3A+Affinity+Asset+Advisors%2C+LLC/26495046.html si-local-file:///var/storage/secattach/20260514/26495046.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++SUTRO+BIOPHARMA%2C+INC.++++++++++++++++++Filed+by%3A+Affinity+Asset+Advisors%2C+LLC/26495046.html Thu, 14 May 2026 16:14:00 -0400 O.02325435 STRO http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++SUTRO+BIOPHARMA%2C+INC.++++++++++++++++++Filed+by%3A+Affinity+Asset+Advisors%2C+LLC/26495046.html si-local-file:///var/storage/secattach/20260514/26495046.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++SUTRO+BIOPHARMA%2C+INC.++++++++++++++++++Filed+by%3A+Affinity+Asset+Advisors%2C+LLC/26495046.html Thu, 14 May 2026 16:14:00 -0400 O.02325435 STRO http://www.streetinsider.com/Press+Releases/Sutro+Biopharma+Reports+First+Quarter+2026+Financial+Results+and+Business+Highlights/26494594.html <p align="center"><em>– On track to report initial safety, PK and early activity from</em> <em>Phase 1 dose-escalation trial of STRO-004, potential best-in-class Tissue Factor ADC, in mid-2026 –</em></p> <p align="center"><em>– Continued advancement of wholly-owned pipeline, including ITGB6 ADC STRO-006 and dual-payload PTK7 program STRO-227, with IND submissions planned in 2026 –</em></p> <p align="center"><em>– First dual-payload iADC from Sutro’s platform entered the clinic under Astellas collaboration; patient dosing underway –</em></p> <p align="center"><em>– Strong balance sheet with $202.6 million in cash, cash equivalents and marketable securities as of March 31, 2026; including gross proceeds from the recent capital raise, supporting http://www.streetinsider.com/Press+Releases/Sutro+Biopharma+Reports+First+Quarter+2026+Financial+Results+and+Business+Highlights/26494594.html Thu, 14 May 2026 16:05:00 -0400 A.35552990 A.50100012 A.50216399 O.00074346 O.02325435 O.07579093 O.22795517 STRO http://www.streetinsider.com/Press+Releases/Sutro+Biopharma+Reports+First+Quarter+2026+Financial+Results+and+Business+Highlights/26494594.html <p align="center"><em>– On track to report initial safety, PK and early activity from</em> <em>Phase 1 dose-escalation trial of STRO-004, potential best-in-class Tissue Factor ADC, in mid-2026 –</em></p> <p align="center"><em>– Continued advancement of wholly-owned pipeline, including ITGB6 ADC STRO-006 and dual-payload PTK7 program STRO-227, with IND submissions planned in 2026 –</em></p> <p align="center"><em>– First dual-payload iADC from Sutro’s platform entered the clinic under Astellas collaboration; patient dosing underway –</em></p> <p align="center"><em>– Strong balance sheet with $202.6 million in cash, cash equivalents and marketable securities as of March 31, 2026; including gross proceeds from the recent capital raise, supporting http://www.streetinsider.com/Press+Releases/Sutro+Biopharma+Reports+First+Quarter+2026+Financial+Results+and+Business+Highlights/26494594.html Thu, 14 May 2026 16:05:00 -0400 A.35552990 A.50100012 A.50216399 O.00074346 O.02325435 O.07579093 O.22795517 STRO http://www.streetinsider.com/Press+Releases/Sutro+Biopharma+Reports+First+Quarter+2026+Financial+Results+and+Business+Highlights/26494594.html <p align="center"><em>– On track to report initial safety, PK and early activity from</em> <em>Phase 1 dose-escalation trial of STRO-004, potential best-in-class Tissue Factor ADC, in mid-2026 –</em></p> <p align="center"><em>– Continued advancement of wholly-owned pipeline, including ITGB6 ADC STRO-006 and dual-payload PTK7 program STRO-227, with IND submissions planned in 2026 –</em></p> <p align="center"><em>– First dual-payload iADC from Sutro’s platform entered the clinic under Astellas collaboration; patient dosing underway –</em></p> <p align="center"><em>– Strong balance sheet with $202.6 million in cash, cash equivalents and marketable securities as of March 31, 2026; including gross proceeds from the recent capital raise, supporting http://www.streetinsider.com/Press+Releases/Sutro+Biopharma+Reports+First+Quarter+2026+Financial+Results+and+Business+Highlights/26494594.html Thu, 14 May 2026 16:05:00 -0400 A.35552990 A.50100012 A.50216399 O.00074346 O.02325435 O.07579093 O.22795517 STRO